The tumor must be located in the supratentorial compartment only (any component involving the brain stem or cerebellum is not allowed)
Radiographic evidence of leptomeningeal dissemination, gliomatosis cerebri, infratentorial tumor, or disease at sites remote from the supratentorial brain.
Histologically confirmed diagnosis of supratentorial glioblastoma.
The tumor must be confined to the supratentorial compartment
Tumor must be supratentorial only
The tumor must be supratentorial
Supratentorial mass effect with greater than 5 mm of midline shift or hydrocephalus
Patients with treated supratentorial metastases are allowed if stable, the patient is off steroids and no evidence of intracranial hemorrhage
Patients must have a recurrent supratentorial WHO grade III or IV malignant glioma based on imaging studies
Prior histopathology consistent with a supratentorial WHO grade III or IV malignant glioma
Patients must have a histologically confirmed diagnosis of supratentorial high-grade glioma or supratentorial ependymoma that is recurrent, progressive or refractory
Subjects must have bi-dimensionally measurable disease, defined as at least one lesion that can be accurately measured in at least two planes\r\n* This disease must be located primarily in the supratentorial region\r\n* Patients with significant disease that is metastatic outside of the supratentorial region are ineligible
Tumors must be supratentorial in location.
The tumor must be primarily supratentorial in location as determined by diagnostic imaging performed preoperatively
Evidence or suspicion of disease metastatic to sites remote from the supratentorial brain
Supratentorial primitive neuroectodermal tumor (PNET) (any M-stage) will be eligible for study entry
Imaging studies show evidence of recurrent, supratentorial tumor(s); the presence of infratentorial tumor is allowed as long as the patient also has supratentorial disease that is amenable to resection or biopsy
Tumor must have a supratentorial component
The tumor must be supratentorial in location
Evidence or suspicion of disease metastatic to sites remote from supratentorial brain
for intratumoral cohorts, supratentorial HGG (WHO grade III or IV)
Elective craniotomy for supratentorial brain tumors
Undergoing elective craniotomy for supratentorial tumors
Location: supratentorial
